IL152825A - Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods - Google Patents

Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods

Info

Publication number
IL152825A
IL152825A IL152825A IL15282501A IL152825A IL 152825 A IL152825 A IL 152825A IL 152825 A IL152825 A IL 152825A IL 15282501 A IL15282501 A IL 15282501A IL 152825 A IL152825 A IL 152825A
Authority
IL
Israel
Prior art keywords
antibody
rabies virus
ser
amino acid
leu
Prior art date
Application number
IL152825A
Other languages
English (en)
Other versions
IL152825A0 (en
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of IL152825A0 publication Critical patent/IL152825A0/xx
Publication of IL152825A publication Critical patent/IL152825A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL152825A 2000-05-16 2001-05-04 Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods IL152825A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20451800P 2000-05-16 2000-05-16
PCT/US2001/014468 WO2001088132A2 (en) 2000-05-16 2001-05-04 Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods

Publications (2)

Publication Number Publication Date
IL152825A0 IL152825A0 (en) 2003-06-24
IL152825A true IL152825A (en) 2009-07-20

Family

ID=22758233

Family Applications (1)

Application Number Title Priority Date Filing Date
IL152825A IL152825A (en) 2000-05-16 2001-05-04 Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods

Country Status (9)

Country Link
US (1) US6890532B2 (https=)
EP (1) EP1282703B1 (https=)
JP (1) JP4819285B2 (https=)
AT (1) ATE411387T1 (https=)
CA (1) CA2419148C (https=)
DE (1) DE60136174D1 (https=)
IL (1) IL152825A (https=)
RU (1) RU2272809C2 (https=)
WO (1) WO2001088132A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
AU2001281151A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
NZ531291A (en) * 2001-08-21 2006-02-24 Univ Jefferson Recombinant anti rabies antibodies MAb JB.1 and Mab 57 and compositions and methods for making and using the same
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
ME01785B (me) * 2005-02-02 2014-09-20 Univ Massachusetts Humana antitijela protiv bjesnila i njihove upotrebe
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
CN103492419B (zh) * 2011-03-18 2015-11-25 赛特瑞恩股份有限公司 可中和狂犬病病毒的结合分子
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
RU2533802C1 (ru) * 2013-08-30 2014-11-20 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Тримеризованное однодоменное антитело, специфически связывающееся с гликопротеином g вируса бешенства, нейтрализующее вирус бешенства
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
CN111166877A (zh) * 2019-12-30 2020-05-19 西安回天血液制品有限责任公司 一种狂犬病人免疫球蛋白的制备方法
CN114958774B (zh) * 2022-05-08 2023-10-27 中国医学科学院医学生物学研究所 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用
CN119431525B (zh) * 2024-10-08 2025-04-11 北京溯本源和生物科技有限公司 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503751A (ja) * 1988-04-07 1990-11-08 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 狂犬病ウイルス細胞を特異的に認識するヒトモノクローナル抗体、それを産生する細胞、それを含有する処方物及びそれら全ての製造方法
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES

Also Published As

Publication number Publication date
US6890532B2 (en) 2005-05-10
JP2004528803A (ja) 2004-09-24
ATE411387T1 (de) 2008-10-15
CA2419148C (en) 2011-07-12
IL152825A0 (en) 2003-06-24
DE60136174D1 (de) 2008-11-27
EP1282703A2 (en) 2003-02-12
RU2272809C2 (ru) 2006-03-27
EP1282703B1 (en) 2008-10-15
CA2419148A1 (en) 2001-11-22
WO2001088132A2 (en) 2001-11-22
WO2001088132A3 (en) 2002-07-18
JP4819285B2 (ja) 2011-11-24
US20030165507A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
CA2419148C (en) Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
KR102141969B1 (ko) 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도
CN1636019B (zh) 重组抗体的组成以及制作和使用方法
RU2764740C1 (ru) Биспецифическое антитело против вируса бешенства и его применение
CN112175073A (zh) 冠状病毒的中和抗体或其抗原结合片段
CN115043938B (zh) SARS-CoV-2及其突变株的抗体及应用
CN108135999B (zh) 针对狂犬病的人抗体及其用途
US20170051046A1 (en) H1n1 flu virus neutralizing antibodies
CN113461812A (zh) 人源化新冠病毒中和性抗体nCoV-00D及其应用
CN103221063B (zh) 针对人类巨细胞病毒(cmv)gb蛋白质的高亲和力人类抗体
CN101375161A (zh) 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白
AU2002332600A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
CN114149504B (zh) Baff-r结合分子及其应用
Cheung et al. A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus
WO2011137569A1 (zh) 人源抗狂犬病毒糖蛋白中和性抗体rvfab3
CN113956352B (zh) 新型冠状病毒中和性抗体及其制备方法与用途
CN111333725B (zh) 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-2及其应用
US20030157112A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
JPWO2016010160A1 (ja) 抗インフルエンザウイルス抗体及びその利用
HK1071898B (en) Recombinant antibodies, and compositions and methods for making and using the same
HK1250482B (en) Human antibodies against rabies and uses thereof
CN120157757A (zh) 幽门螺旋杆菌单链抗体及其用途

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees